Results 1 to 10 of about 2,029,665 (367)

Resveratrol protects against chronic alcohol-induced liver disease in a rat model

open access: yesSTEMedicine, 2022
Hepatic ethanol metabolism participates in the pathogenesis of alcoholic liver disease (ALD). We aimed to evaluate the protecting effects and underlying mechanisms of Resveratrol against ALD.
Hanzhang Zhu   +3 more
doaj   +1 more source

CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway

open access: yesJournal of Translational Medicine, 2023
Background Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence.
Chuanzheng Wang   +7 more
doaj   +1 more source

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

open access: yesNew England Journal of Medicine, 2020
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with
R. Finn   +20 more
semanticscholar   +1 more source

Heat shock protein HSPA13 promotes hepatocellular carcinoma progression by stabilizing TANK

open access: yesCell Death Discovery, 2023
HSPA13, an important member of the heat shock protein family, plays an essential role in the oncogenesis of many organs, but the mechanism and function in hepatocellular carcinoma (HCC) is still unclear.
Xuesong Cen   +9 more
doaj   +1 more source

Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)

open access: yesHepatology Research, 2023
The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence‐based medicine and partly to the Grading of Recommendations Assessment ...
K. Hasegawa   +26 more
semanticscholar   +1 more source

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

open access: yesNEJM Evidence, 2022
Tremelimumab/Durvalumab for Hepatocellular CarcinomaThis trial examined overall survival (OS) with tremelimumab plus durvalumab, durvalumab alone, or sorafenib in untreated patients with hepatocellular cancer who were not candidates for locoregional ...
G. Abou-Alfa   +30 more
semanticscholar   +1 more source

RBCK1 promotes hepatocellular carcinoma metastasis and growth by stabilizing RNF31

open access: yesCell Death Discovery, 2022
RNF31 (HOIP), RBCK1 (HOIL-1L), and SHARPIN are subunits of the linear ubiquitin chain assembly complex. Their function and specific molecular mechanisms in hepatocellular carcinoma (HCC) have not been reported previously.
Xijun Chen   +5 more
doaj   +1 more source

β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation

open access: yesFrontiers in Oncology, 2021
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally. Currently there is a lack of tumor-selective and efficacious therapies for hepatocellular carcinoma. β-Lapachone (ARQ761 in clinical form) selectively kill NADPH:
Wenxiu Zhao   +15 more
doaj   +1 more source

Long Noncoding RNA HCAL Facilitates the Growth and Metastasis of Hepatocellular Carcinoma by Acting as a ceRNA of LAPTM4B

open access: yesMolecular Therapy: Nucleic Acids, 2017
Long noncoding RNAs (lncRNAs) are a new class of regulatory noncoding RNAs. Emerging evidences indicate that lncRNAs play a critical role in the development of hepatocellular carcinoma (HCC).
Cheng-Rong Xie   +10 more
doaj   +1 more source

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. [PDF]

open access: yes, 2016
Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options.
Alanis, Lourdes   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy